BMEA (Biomea Fusion) Tariff Resilience Score: 6/10 (As of Jul. 05, 2026)


BMEA Biomea Fusion Inc BMEA
31 GF Score
Price $1.42
! 1 Warning Sign
View Full Analysis

What is Biomea Fusion Tariff Resilience Score?

Biomea Fusion BMEA +3.68% 31 Tariff Resilience Score is 6 as of Jul. 05, 2026. GuruFocus rates BMEA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,369 Biotechnology companies, Biomea Fusion ranks better than 75.97% on this metric.

Biomea Fusion has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

Biomea Fusion has Biomea Fusion Inc is a biotech firm with potential exposure to tariffs on imported research materials. However, its focus on innovation and potential for alternative suppliers offers some mitigation against tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Biomea Fusion might have Average Resilient.

Biomea Fusion  (NAS:BMEA) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Biomea Fusion Tariff Resilience Score Related Terms

BMEA vs ANIX, PMN, ATRA: Tariff Resilience Score Comparison

For the Biotechnology subindustry, Biomea Fusion's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Biomea Fusion Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biomea Fusion's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Biomea Fusion's Tariff Resilience Score falls into.


BMEA
31GF Score
Biomea Fusion Inc BMEA
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
Biomea Fusion (BMEA) has a Tariff Resilience Score of 6 as of Jul. 05, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Biomea Fusion ranks #329 out of 1369 companies in the Biotechnology industry, placing it in the top 24%.
Is Biomea Fusion's Tariff Resilience Score too high?
Biomea Fusion's current Tariff Resilience Score is 6. The Biotechnology industry median Tariff Resilience Score is 4.00. Biomea Fusion's value of 6 is 50% above this industry median. Based on the distribution chart, Biomea Fusion ranks #329 out of 1369 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Biomea Fusion has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Biomea Fusion's Tariff Resilience Score compare to ANIX and PMN?
According to the Biotechnology industry distribution chart, Biomea Fusion ranks #329 out of 1369 companies for Tariff Resilience Score. This places Biomea Fusion in the top 24% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. Biomea Fusion's value of 6 is 50% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,369 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomea Fusion's current Tariff Resilience Score of 6 is 50% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomea Fusion's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomea Fusion stock overvalued right now?
Biomea Fusion (BMEA) has a current Tariff Resilience Score of 6. The current Tariff Resilience Score is 6 and 50% above the Biotechnology industry median of 4.00. Biomea Fusion's overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Biomea Fusion (BMEA), the current Tariff Resilience Score is 6 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biomea Fusion Business Description

Address 1599 Industrial Road, San Carlos, CA, USA, 94070
Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.
31GF Score

Get the complete analysis for BMEA

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.42
Price